Hibsago

News

GSK's antisense-based drug for chronic hepatitis B virus (HBV) infection, Hibsago, has been approved in the US, its second major market after Japan.

News

Novo continues to build the case for its new weight-loss candidate CagriSema, pointing to new data that show strong efficacy in women.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.